News

Saratoga Investment Corp. Posts Strong Fiscal Q2 2026 Results

Saratoga Investment Corp. Posts Strong Fiscal Q2 2026 Results

Saratoga Investment Corp. Reports Impressive Fiscal Q2 2026 Results

Highlights Include 3.6% Increase in NAV From Previous Quarter

Quarterly ROE of 13.8% Surpassing Industry Average of 7.3%

Zollege Investment Back on Track; Minimal Non-Accrual Investments

Saratoga Investment Corp. (NYSE: SAR), a prominent player in the business development company sector, has released its financial performance metrics for the second quarter of fiscal 2026, ending August 31, 2025. The company has demonstrated noteworthy growth in several key financial indicators, reflecting robust operational strength amid market fluctuations.

Fiscal Q2 2026 Financial Overview

The company reported total assets under management (AUM) reaching $995.3 million, a robust growth from $968.3 million in the previous quarter. This reflects a steady increase of 2.8% as compared to the last period. The net asset value (NAV) surged by 3.6% to $410.5 million, resulting in an increase in NAV per share to $25.61, up from $25.52.

Key Financial Metrics

  • Total Investment Income: $30.6 million
  • Net Investment Income per Share: $0.58
  • Earnings per Share: $0.84
  • Quarterly Dividend: $0.75 per share
  • Annualized Yield Based on Dividend: 12.3%

Strong Returns and Portfolio Performance

Chairman and CEO Christian L. Oberbeck remarked on the quarter, stating, “Our ongoing commitment to effective portfolio management has resulted in impressive NAV growth and solid earnings. Additionally, the return of our Zollege investment to accrual status marks a significant improvement, minimizing our non-accrual investments to just one, which represents a mere 0.2% of the portfolio's fair value.”

Dividend Distribution History

Saratoga Investment maintains a consistent dividend distribution history, with a declaration of a base dividend of $0.25 per share per month, equating to $0.75 for the quarter. This translates into an attractive yield for stakeholders, particularly in the context of such challenging market conditions.

Acknowledging Market Dynamics

The company reported competitive dynamics in the market, allowing for multiple debt repayments and promising new originations. In the second quarter alone, they originated an impressive $52.2 million across various follow-ons and investments in high-quality structured credit securities.

Furthermore, the firm’s management team has been proactive, forming strong sponsor relationships which have been instrumental in creating fresh investment opportunities. This outset is designed to enhance run-rate earnings steadily.

Financial Metrics Visualized

Saratoga Investment's financial results from the quarter highlight several key metrics:

  • ROE for the quarter: 13.8%, yielding a last twelve months (LTM) ROE of 9.1%
  • Annual Amount Repaid: Continuous repayments and restructuring strategies have progressively enhanced cash positions, now at $200.8 million.
  • Total Portfolio Value: The portfolio increased in fair value by $3.8 million during the quarter, showing resilience even in unstable market conditions.

Liquidity and Capital Resource Management

Saratoga Investment's liquidity position remains strong, with $70 million available through its credit facilities and total accessible undrawn borrowing power of $406.8 million. This financial flexibility positions the company well, enabling it to navigate future economic uncertainties confidently.

Assessment of Investment Strategy

The ongoing strategy of investing in senior and unitranche leveraged loans presents a solid foundation for strong risk-adjusted returns, while actively focusing on securing high-quality investments. The company is now managing a diversified portfolio that emphasizes sound underwriting practices.

Frequently Asked Questions

What is the NAV of Saratoga Investment Corp. for Q2 2026?

The NAV is reported at $410.5 million for the second quarter of fiscal 2026.

How much is the quarterly dividend announced?

The company has declared a base dividend of $0.75 per share for Q2 2026.

What factors contribute to the company’s recent growth?

Saratoga Investment's growth can be attributed to effective portfolio management, increased originations, and a strong cash position for future investments.

How does the company manage its liquidity?

Through strategic borrowing options and maintaining a substantial amount of cash reserves, they effectively navigate market uncertainties.

What is the company's focus for future investments?

The company focuses on senior and unitranche leveraged loans, alongside developing productive relationships with strong sponsors for new investment opportunities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 32

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 31

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 32

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 36

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

ZTO Express Highlights Convertible Note Repurchase Opportunity

Updated Category News Views 114

Understanding ZTO Express's Convertible Note Repurchase Right ZTO Express (Cayman) Inc. (NYSE: ZTO), a key player in the express delivery sector, recently informed its bondholders about their rights regarding the 1.50% Convertible Senior Notes due 2027. The company offers an opportunity for holders to request the repurchase of their notes in cash, giving them a strategic...

Continue Reading
EVERSANA's AI Expands: Revolutionizing Life Sciences

Updated Category News Views 11

A Bold Leap in AI Commercialization Look, fresh off the press, EVERSANA is making some waves. They’ve expanded their AI-powered commercialization platform, aiming to overhaul life sciences operations. Sounds like a mouthful, right? Well, let's break it down. This expansion isn't just a facelift; it's part of a bigger vision to create a nimble, AI-native ecosystem for...

Continue Reading
Wabtec Corporation's Q3 Performance: Growth and Opportunities

Updated Category News Views 93

Wabtec Corporation Delivers Strong Third Quarter Results Wabtec Corporation (NYSE: WAB) has announced a solid performance for the third quarter, reporting a notable 4.5% increase in sales, reaching $2.7 billion compared to the same period last year. This growth can be attributed to the robust performance in its freight and transit sectors. The company also shared that the...

Continue Reading
Exploring Job Creation and Economic Growth by Argosy Investments

Updated Category News Views 119

Argosy Real Estate Partners and Economic Development Argosy Real Estate Partners, a dedicated private real estate investment manager, has recently shared compelling insights from its Opportunity Zone Economic Impact Analysis. The firm emphasizes its commitment to fostering positive growth in communities by investing in Qualified Opportunity Zones. This analysis showcases...

Continue Reading
Join Vow ASA for the Exciting Q3 2024 Results Presentation

Updated Category News Views 101

Vow ASA Invites You to Its Third Quarter 2024 Presentation Vow ASA (OSE: VOW) is gearing up to unveil its much-anticipated report for the third quarter of 2024. Mark your calendars for this significant event on a Tuesday morning, when the company's financial performance and insights will be shared with the world. Presentation Details The results will be available for...

Continue Reading